美国≥65岁成人肺炎球菌疫苗接种的成本效果与健康影响
该研究用马尔可夫模型模拟美国65岁人群,比较不同肺炎球菌疫苗接种策略。作者认为对免疫正常的美国老年人省略结合疫苗可能具有经济合理性,尤其对黑人老年人。
要点
- 省略结合疫苗的策略减少0.3%至0.9%的病例和死亡,在黑人人群中花费更低。
核心结论
- 对免疫正常的美国老年人省略肺炎球菌结合疫苗的接种策略可能具有经济合理性,尤其对黑人老年人。
- 使用两种肺炎球菌疫苗更有效但费用显著更高。
研究设计与样本
- 研究使用马尔可夫状态转换模型,模拟美国65岁人群队列,基于年龄和人群特异性数据划分健康状态,采用终身时间 horizon 和医疗保健视角。
- 黑人人群队列因疾病风险更高和疫苗 uptake 更低而单独分析。
- 模型参数来自美国疾病控制与预防中心主动核心细菌监测网络、全国健康访谈调查和全国住院患者样本数据。
- 数据收集和分析于2018年进行。
主要发现
- 替代策略减少0.3%至0.9%的病例和死亡。
关键数值与推荐
- 替代策略减少0.3%至0.9%的病例和死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Recommending both the conjugate and polysaccharide pneumococcal vaccines to all U.S. seniors may have little public health impact and be economically unreasonable. Public health impact and cost-effectiveness of using both vaccines in all adults aged ≥65 years were estimated compared with an alternative strategy (omitting pneumococcal conjugate vaccine in the nonimmunocompromised) and with the newly revised recommendation (giving or omitting conjugate vaccine based on patient-physician shared decision making). METHODS: Strategies were examined in hypothetical U.S. 65-year-old population cohorts and segmented into health states based on age- and population-specific data in a Markov state-transition model with a lifetime time horizon from a healthcare perspective. Black population cohorts were examined separately given greater illness risk and lower vaccine uptake. Model parameters came from the Centers for Disease Control Active Core Bacterial Surveillance network, National Health Interview Survey, and Nationwide Inpatient Sample data. Outcomes included incremental costs per quality-adjusted life year gained and pneumococcal disease outcomes for each strategy. Data were gathered and analysis performed in 2018. RESULTS: Giving both vaccines, either routinely or with shared decision making, was most effective, reducing pneumococcal disease incidence compared with no vaccination, but costing $765,000-$2.18 million/quality-adjusted life year gained. Depending on examined population and scenario, the alternative strategy cost $65,700-$226,700/quality-adjusted life year gained (less in black populations) and reduced cases and deaths by 0.3%-0.9%. CONCLUSIONS: A vaccination strategy that omits pneumococcal conjugate vaccine in immunocompetent U.S. seniors may be economically reasonable, particularly for black seniors. Use of both pneumococcal vaccines was more effective but substantially more expensive.
引用
- Wateska AR, Nowalk MP, Lin CJ, et al. Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations. Am J Prev Med. 2020. PMID: 32001052. doi:10.1016/j.amepre.2019.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。